Medicine recalls
|
| |
| Batch Recall of Gastrografin Liq Oral/Rectal |
| |
The Department of Health (DH) today (24 February ) endorsed a licensed drug wholesaler, Bayer Healthcare Limited (Bayer), to recall a total of 5 batches (batch number: MA04HF2-H1, MA04MPR-H1, MA04MPR-H2, MA04P3R-H1, MA04S8L-H1) of the product, namely Gastrografin Liq Oral/Rectal (Hong Kong Registration number: HK-46076) from the market as a precautionary measure due to the presence of impurity in the product.
The DH received notification from Bayer that the overseas manufacturer of the concerned product is recalling the above batches of Gastrografin Liq Oral/Rectal as they exceed the accepted level of an impurity, N-Nitroso-Meglumine (NO-Meglumine). NO-Meglumine is classified as a probable human carcinogen based on results from laboratory tests. As a precautionary measure, Bayer is voluntarily recalling the affected batches of product from the market.
The above product, containing meglumine amidotrizoate and sodium amidotrizoate, is a contrast medium used for examination of the gastrointestinal tract. According to Bayer, the affected batches had been imported into Hong Kong and supplied to Hospital Authority, private hospitals, private doctors, and exported to Macao.
Bayer has set up a hotline 8100 2755 to answer related enquiries.
So far, the DH has not received any adverse reaction report in connection with the product. The DH will closely monitor the recall.
Patients who have used the above product should consult their healthcare professionals if in doubt.
Ends/ Tuesday, February 24, 2026 |
| |
